# Pendulum Therapeutics Pendulum Therapeutics develops probiotic supplements targeting metabolic health and glucose control. The company's flagship product, Pendulum Glucose Control, is a live probiotic formulation clinically shown to lower A1C and blood glucose spikes in people with type 2 diabetes; additional products include Pendulum Akkermansia, Pendulum Metabolic Daily, and Pendulum Butyricum. Pendulum was founded by Colleen Cutcliffe, who serves as CEO, and John Eid, Chief Science Officer and co-founder. The company sells directly to consumers through subscription and also distributes through healthcare professional channels and platforms like Fullscript. Pendulum's products are formulated with proprietary, clinically-studied microbiome-targeted compositions designed to address specific metabolic conditions through gut health restoration.